



Clinical trial results:

Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2012-004792-39 |
| Trial protocol | ES GB DE |
| Global end of trial date | 13 July 2017 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 25 November 2017 |
| First version publication date | 25 November 2017 |

Trial information

Trial identification

| | |
|-----------------------|---------|
| Sponsor protocol code | M12-999 |
|-----------------------|---------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01782495 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | AbbVie Deutschland GmbH & Co. KG |
| Sponsor organisation address | AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6-4UB |
| Public contact | Global Medical Services, AbbVie, 001 800-633-9110, |
| Scientific contact | Emily Dumas, AbbVie, emily.dumas@abbvie.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 13 July 2017 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|--------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 13 July 2017 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 with or without ABT-333 and with or without ribavirin (RBV) in adult liver or renal transplant recipients with hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4) infection.

Protection of trial subjects:

Subject read and understood the information provided about the study and gave written permission.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 25 February 2013 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Australia: 8 |
| Country: Number of subjects enrolled | France: 2 |
| Country: Number of subjects enrolled | Germany: 3 |
| Country: Number of subjects enrolled | United Kingdom: 14 |
| Country: Number of subjects enrolled | Spain: 16 |
| Country: Number of subjects enrolled | United States: 86 |
| Worldwide total number of subjects | 129 |
| EEA total number of subjects | 35 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |

| | |
|----------------------|----|
| Adults (18-64 years) | 97 |
| From 65 to 84 years | 32 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study included a 35-day screening period.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-------|
| Are arms mutually exclusive? | Yes |
| Arm title | Arm A |

Arm description:

Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | ombitasvir/paritaprevir/ritonavir |
| Investigational medicinal product code | |
| Other name | Viekirax, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

ombitasvir (25 mg) coformulated with paritaprevir (150 mg) and ritonavir (100 mg) twice daily

| | |
|--|------------------|
| Investigational medicinal product name | dasabuvir |
| Investigational medicinal product code | |
| Other name | Exviera, ABT-333 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

dasabuvir 250 mg twice daily

| | |
|--|-----------|
| Investigational medicinal product name | ribavirin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Weight-based (dosed 1,000 or 1,200 mg daily divided twice a day)

| | |
|------------------|-------|
| Arm title | Arm B |
|------------------|-------|

Arm description:

Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|--|
| Investigational medicinal product name | ombitasvir/paritaprevir/ritonavir |
| Investigational medicinal product code | |
| Other name | Viekirax, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: ombitasvir (25 mg) coformulated with paritaprevir (150 mg) and ritonavir (100 mg) twice daily | |
| Investigational medicinal product name | dasabuvir |
| Investigational medicinal product code | |
| Other name | Exviera, ABT-333 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: dasabuvir 250 mg twice daily | |
| Investigational medicinal product name | ribavirin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: Weight-based (dosed 1,000 or 1,200 mg daily divided twice a day) | |
| Arm title | Arm C |
| Arm description: Liver transplant receipts with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks. | |
| Arm type | Experimental |
| Investigational medicinal product name | ombitasvir/paritaprevir/ritonavir |
| Investigational medicinal product code | |
| Other name | Viekirax, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: ombitasvir (25 mg) coformulated with paritaprevir (150 mg) and ritonavir (100 mg) twice daily | |
| Investigational medicinal product name | dasabuvir |
| Investigational medicinal product code | |
| Other name | Exviera, ABT-333 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: dasabuvir 250 mg twice daily | |
| Arm title | Arm D |
| Arm description: Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks. | |
| Arm type | Experimental |

| | |
|--|--|
| Investigational medicinal product name | ombitasvir/paritaprevir/ritonavir |
| Investigational medicinal product code | |
| Other name | Viekirax, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: ombitasvir (25 mg) coformulated with paritaprevir (150 mg) and ritonavir (100 mg) twice daily | |
| Investigational medicinal product name | dasabuvir |
| Investigational medicinal product code | |
| Other name | Exviera, ABT-333 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: dasabuvir 250 mg twice daily | |
| Investigational medicinal product name | ribavirin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: Weight-based (dosed 1,000 or 1,200 mg daily divided twice a day) | |
| Arm title | Arm E |
| Arm description: Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks. | |
| Arm type | Experimental |
| Investigational medicinal product name | ombitasvir/paritaprevir/ritonavir |
| Investigational medicinal product code | |
| Other name | Viekirax, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: ombitasvir (25 mg) coformulated with paritaprevir (150 mg) and ritonavir (100 mg) twice daily | |
| Investigational medicinal product name | dasabuvir |
| Investigational medicinal product code | |
| Other name | Exviera, ABT-333 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: dasabuvir 250 mg twice daily | |
| Investigational medicinal product name | ribavirin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: Weight-based (dosed 1,000 or 1,200 mg daily divided twice a day) | |
| Arm title | Arm F |

Arm description:

Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | ombitasvir/paritaprevir/ritonavir |
| Investigational medicinal product code | |
| Other name | Viekirax, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

ombitasvir (25 mg) coformulated with paritaprevir (150 mg) and ritonavir (100 mg) twice daily

| | |
|--|------------------|
| Investigational medicinal product name | dasabuvir |
| Investigational medicinal product code | |
| Other name | Exviera, ABT-333 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

dasabuvir 250 mg twice daily

| | |
|--|-----------|
| Investigational medicinal product name | ribavirin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Weight-based (dosed 1,000 or 1,200 mg daily divided twice a day)

| | |
|------------------|-------|
| Arm title | Arm G |
|------------------|-------|

Arm description:

Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | ombitasvir/paritaprevir/ritonavir |
| Investigational medicinal product code | |
| Other name | Viekirax, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

ombitasvir (25 mg) coformulated with paritaprevir (150 mg) and ritonavir (100 mg) twice daily

| | |
|--|------------------|
| Investigational medicinal product name | dasabuvir |
| Investigational medicinal product code | |
| Other name | Exviera, ABT-333 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

dasabuvir 250 mg twice daily

| | |
|------------------|-------|
| Arm title | Arm H |
|------------------|-------|

Arm description:

Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | ombitasvir/paritaprevir/ritonavir |
| Investigational medicinal product code | |
| Other name | Viekirax, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

ombitasvir (25 mg) coformulated with paritaprevir (150 mg) and ritonavir (100 mg) twice daily

| | |
|--|------------------|
| Investigational medicinal product name | dasabuvir |
| Investigational medicinal product code | |
| Other name | Exviera, ABT-333 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

dasabuvir 250 mg twice daily

| | |
|--|-----------|
| Investigational medicinal product name | ribavirin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Weight-based (dosed 1,000 or 1,200 mg daily divided twice a day)

| | |
|------------------|-------|
| Arm title | Arm I |
|------------------|-------|

Arm description:

Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | ombitasvir/paritaprevir/ritonavir |
| Investigational medicinal product code | |
| Other name | Viekirax, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

ombitasvir (25 mg) coformulated with paritaprevir (150 mg) and ritonavir (100 mg) twice daily

| | |
|--|------------------|
| Investigational medicinal product name | dasabuvir |
| Investigational medicinal product code | |
| Other name | Exviera, ABT-333 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

dasabuvir 250 mg twice daily

| | |
|------------------|-------|
| Arm title | Arm J |
|------------------|-------|

Arm description:

Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|--|
| Investigational medicinal product name | ombitasvir/paritaprevir/ritonavir |
| Investigational medicinal product code | |
| Other name | Viekirax, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

ombitasvir (25 mg) coformulated with paritaprevir (150 mg) and ritonavir (100 mg) twice daily

| | |
|--|-----------|
| Investigational medicinal product name | ribavirin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Weight-based (dosed 1,000 or 1,200 mg daily divided twice a day)

| | |
|------------------|-------|
| Arm title | Arm K |
|------------------|-------|

Arm description:

Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | ombitasvir/paritaprevir/ritonavir |
| Investigational medicinal product code | |
| Other name | Viekirax, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

ombitasvir (25 mg) coformulated with paritaprevir (150 mg) and ritonavir (100 mg) twice daily

| | |
|--|-----------|
| Investigational medicinal product name | ribavirin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Weight-based (dosed 1,000 or 1,200 mg daily divided twice a day)

| Number of subjects in period 1 | Arm A | Arm B | Arm C |
|---------------------------------------|-------|-------|-------|
| Started | 34 | 27 | 13 |
| Completed | 34 | 26 | 13 |
| Not completed | 0 | 1 | 0 |
| Adverse event | - | - | - |
| Withdrew consent | - | 1 | - |

| Number of subjects in period 1 | Arm D | Arm E | Arm F |
|---------------------------------------|-------|-------|-------|
| Started | 4 | 2 | 22 |
| Completed | 4 | 2 | 22 |
| Not completed | 0 | 0 | 0 |

| | | | |
|------------------|---|---|---|
| Adverse event | - | - | - |
| Withdrew consent | - | - | - |

| Number of subjects in period 1 | Arm G | Arm H | Arm I |
|---------------------------------------|-------|-------|-------|
| Started | 12 | 9 | 3 |
| Completed | 12 | 6 | 3 |
| Not completed | 0 | 3 | 0 |
| Adverse event | - | 2 | - |
| Withdrew consent | - | 1 | - |

| Number of subjects in period 1 | Arm J | Arm K |
|---------------------------------------|-------|-------|
| Started | 2 | 1 |
| Completed | 2 | 1 |
| Not completed | 0 | 0 |
| Adverse event | - | - |
| Withdrew consent | - | - |

Baseline characteristics

Reporting groups

| | |
|--|-------|
| Reporting group title | Arm A |
| Reporting group description: Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks. | |
| Reporting group title | Arm B |
| Reporting group description: Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks. | |
| Reporting group title | Arm C |
| Reporting group description: Liver transplant recipients with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks. | |
| Reporting group title | Arm D |
| Reporting group description: Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks. | |
| Reporting group title | Arm E |
| Reporting group description: Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks. | |
| Reporting group title | Arm F |
| Reporting group description: Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks. | |
| Reporting group title | Arm G |
| Reporting group description: Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks. | |
| Reporting group title | Arm H |
| Reporting group description: Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks. | |
| Reporting group title | Arm I |
| Reporting group description: Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks. | |
| Reporting group title | Arm J |
| Reporting group description: Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks. | |
| Reporting group title | Arm K |
| Reporting group description: Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received | |

| Reporting group values | Arm A | Arm B | Arm C |
|------------------------|-------|-------|-------|
| Number of subjects | 34 | 27 | 13 |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|--|--------|--------|--------|
| Age continuous | | | |
| Intent-to-treat (ITT) population: All participants who received at least 1 dose of study drug. 77777=The estimated standard deviation of one sample is undefined | | | |
| Units: years | | | |
| arithmetic mean | 59.6 | 58 | 61.8 |
| standard deviation | ± 6.62 | ± 6.66 | ± 5.76 |
| Gender categorical | | | |
| Intent-to-treat (ITT) population: All participants who received at least 1 dose of study drug. | | | |
| Units: Subjects | | | |
| Female | 7 | 4 | 5 |
| Male | 27 | 23 | 8 |

| Reporting group values | Arm D | Arm E | Arm F |
|------------------------|-------|-------|-------|
| Number of subjects | 4 | 2 | 22 |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|--|---------|--------|--------|
| Age continuous | | | |
| Intent-to-treat (ITT) population: All participants who received at least 1 dose of study drug. 77777=The estimated standard deviation of one sample is undefined | | | |
| Units: years | | | |
| arithmetic mean | 59.8 | 78 | 58.3 |
| standard deviation | ± 10.78 | ± 1.41 | ± 9.35 |
| Gender categorical | | | |
| Intent-to-treat (ITT) population: All participants who received at least 1 dose of study drug. | | | |
| Units: Subjects | | | |
| Female | 0 | 2 | 2 |
| Male | 4 | 0 | 20 |

| Reporting group values | Arm G | Arm H | Arm I |
|------------------------|-------|-------|-------|
| Number of subjects | 12 | 9 | 3 |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|--|--------|-----|--------|
| Age continuous | | | |
| Intent-to-treat (ITT) population: All participants who received at least 1 dose of study drug. 77777=The estimated standard deviation of one sample is undefined | | | |
| Units: years | | | |
| arithmetic mean | 62.2 | 58 | 57.3 |
| standard deviation | ± 7.64 | ± 8 | ± 9.29 |

| | | | |
|--|----|---|---|
| Gender categorical | | | |
| Intent-to-treat (ITT) population: All participants who received at least 1 dose of study drug. | | | |
| Units: Subjects | | | |
| Female | 2 | 2 | 1 |
| Male | 10 | 7 | 2 |

| Reporting group values | Arm J | Arm K | Total |
|-------------------------------|-------|-------|-------|
| Number of subjects | 2 | 1 | 129 |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|--|------------|-------------|-----|
| Age continuous | | | |
| Intent-to-treat (ITT) population: All participants who received at least 1 dose of study drug. 77777=The estimated standard deviation of one sample is undefined | | | |
| Units: years | | | |
| arithmetic mean | 63.5 | 50 | |
| standard deviation | ± 7.78 | ± 77777 | - |
| Gender categorical | | | |
| Intent-to-treat (ITT) population: All participants who received at least 1 dose of study drug. | | | |
| Units: Subjects | | | |
| Female | 0 | 0 | 25 |
| Male | 2 | 1 | 104 |

End points

End points reporting groups

| | |
|--|-------|
| Reporting group title | Arm A |
| Reporting group description: Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks. | |
| Reporting group title | Arm B |
| Reporting group description: Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks. | |
| Reporting group title | Arm C |
| Reporting group description: Liver transplant recipients with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks. | |
| Reporting group title | Arm D |
| Reporting group description: Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks. | |
| Reporting group title | Arm E |
| Reporting group description: Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks. | |
| Reporting group title | Arm F |
| Reporting group description: Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks. | |
| Reporting group title | Arm G |
| Reporting group description: Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks. | |
| Reporting group title | Arm H |
| Reporting group description: Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks. | |
| Reporting group title | Arm I |
| Reporting group description: Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks. | |
| Reporting group title | Arm J |
| Reporting group description: Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks. | |
| Reporting group title | Arm K |
| Reporting group description: Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received | |

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

| | |
|-----------------|---|
| End point title | Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) ^[1] |
|-----------------|---|

End point description:

SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification [<LLOQ]) 12 weeks after the last dose of study drug. Participants with missing data after backward imputation were imputed as nonresponders.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

12 weeks after the last actual dose of study drug

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive data are summarized for this end point per protocol.

| End point values | Arm A | Arm B | Arm C | Arm D |
|-----------------------------------|---------------------|---------------------|-------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 34 ^[2] | 27 ^[3] | 13 ^[4] | 4 ^[5] |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 97.1 (85.1 to 99.5) | 96.3 (81.7 to 99.3) | 100 (77.2 to 100) | 100 (51 to 100) |

Notes:

[2] - All participants who received at least 1 dose of study drug (ITT population).

[3] - All participants who received at least 1 dose of study drug (ITT population).

[4] - All participants who received at least 1 dose of study drug (ITT population).

[5] - All participants who received at least 1 dose of study drug (ITT population).

| End point values | Arm E | Arm F | Arm G | Arm H |
|-----------------------------------|-------------------|---------------------|-------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 ^[6] | 22 ^[7] | 12 ^[8] | 9 ^[9] |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 100 (34.2 to 100) | 95.5 (78.2 to 99.2) | 100 (75.8 to 100) | 66.7 (35.4 to 87.9) |

Notes:

[6] - All participants who received at least 1 dose of study drug (ITT population).

[7] - All participants who received at least 1 dose of study drug (ITT population).

[8] - All participants who received at least 1 dose of study drug (ITT population).

[9] - All participants who received at least 1 dose of study drug (ITT population).

| End point values | Arm I | Arm J | Arm K | |
|-----------------------------------|-------------------|-------------------|-------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 3 ^[10] | 2 ^[11] | 1 ^[12] | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 100 (43.9 to 100) | 100 (34.2 to 100) | 100 (20.7 to 100) | |

Notes:

[10] - All participants who received at least 1 dose of study drug (ITT population).

[11] - All participants who received at least 1 dose of study drug (ITT population).

[12] - All participants who received at least 1 dose of study drug (ITT population).

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24)

| | |
|-----------------|--|
| End point title | Percentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24) |
|-----------------|--|

End point description:

SVR24 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification [<LLOQ]) 24 weeks after the last dose of study drug. Participants with missing data after backward imputation were imputed as nonresponders.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 weeks after the last actual dose of study drug

| End point values | Arm A | Arm B | Arm C | Arm D |
|-----------------------------------|---------------------|---------------------|--------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 34 ^[13] | 27 ^[14] | 13 ^[15] | 4 ^[16] |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 97.1 (85.1 to 99.5) | 96.3 (81.7 to 99.3) | 100 (77.2 to 100) | 100 (51 to 100) |

Notes:

[13] - All participants who received at least 1 dose of study drug (ITT population).

[14] - All participants who received at least 1 dose of study drug (ITT population).

[15] - All participants who received at least 1 dose of study drug (ITT population).

[16] - All participants who received at least 1 dose of study drug (ITT population).

| End point values | Arm E | Arm F | Arm G | Arm H |
|-----------------------------------|-------------------|---------------------|--------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 ^[17] | 22 ^[18] | 12 ^[19] | 9 ^[20] |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 100 (34.2 to 100) | 95.5 (78.2 to 99.2) | 100 (75.8 to 100) | 66.7 (35.4 to 87.9) |

Notes:

[17] - All participants who received at least 1 dose of study drug (ITT population).

[18] - All participants who received at least 1 dose of study drug (ITT population).

[19] - All participants who received at least 1 dose of study drug (ITT population).

[20] - All participants who received at least 1 dose of study drug (ITT population).

| End point values | Arm I | Arm J | Arm K | |
|-----------------------------|-------------------|-------------------|-------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 3 ^[21] | 2 ^[22] | 1 ^[23] | |

| | | | | |
|-----------------------------------|-------------------|-------------------|-------------------|--|
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 100 (43.9 to 100) | 100 (34.2 to 100) | 100 (20.7 to 100) | |

Notes:

[21] - All participants who received at least 1 dose of study drug (ITT population).

[22] - All participants who received at least 1 dose of study drug (ITT population).

[23] - All participants who received at least 1 dose of study drug (ITT population).

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With On-treatment Virologic Failure

| | |
|-----------------|--|
| End point title | Percentage of Participants With On-treatment Virologic Failure |
|-----------------|--|

End point description:

On-treatment virologic failure was defined as confirmed increase of $> 1 \log(\text{subscript})10(\text{subscript})$ IU/mL above the lowest value post-baseline HCV RNA during treatment, or confirmed HCV RNA \geq LLOQ at any point during treatment after HCV RNA $<$ LLOQ, or HCV RNA \geq LLOQ persistently during treatment with at least 6 weeks (≥ 36 days) of treatment.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 12 weeks (for 12-week treatment) or 24 weeks (for 24-week treatment)

| End point values | Arm A | Arm B | Arm C | Arm D |
|-----------------------------------|--------------------|--------------------|--------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 34 ^[24] | 27 ^[25] | 13 ^[26] | 4 ^[27] |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 0 (0 to 10.2) | 3.7 (0.7 to 18.3) | 0 (0 to 22.8) | 0 (0 to 49) |

Notes:

[24] - All participants who received at least 1 dose of study drug (ITT population).

[25] - All participants who received at least 1 dose of study drug (ITT population).

[26] - All participants who received at least 1 dose of study drug (ITT population).

[27] - All participants who received at least 1 dose of study drug (ITT population).

| End point values | Arm E | Arm F | Arm G | Arm H |
|-----------------------------------|-------------------|--------------------|--------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 ^[28] | 22 ^[29] | 12 ^[30] | 9 ^[31] |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 0 (0 to 65.8) | 0 (0 to 14.9) | 0 (0 to 24.2) | 0 (0 to 29.9) |

Notes:

[28] - All participants who received at least 1 dose of study drug (ITT population).

[29] - All participants who received at least 1 dose of study drug (ITT population).

[30] - All participants who received at least 1 dose of study drug (ITT population).

[31] - All participants who received at least 1 dose of study drug (ITT population).

| End point values | Arm I | Arm J | Arm K | |
|-----------------------------------|-------------------|-------------------|-------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 3 ^[32] | 2 ^[33] | 1 ^[34] | |
| Units: percentage of participants | | | | |

| | | | | |
|----------------------------------|---------------|---------------|---------------|--|
| number (confidence interval 95%) | 0 (0 to 56.1) | 0 (0 to 65.8) | 0 (0 to 79.3) | |
|----------------------------------|---------------|---------------|---------------|--|

Notes:

[32] - All participants who received at least 1 dose of study drug (ITT population).

[33] - All participants who received at least 1 dose of study drug (ITT population).

[34] - All participants who received at least 1 dose of study drug (ITT population).

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Post-treatment Relapse

| | |
|-----------------|--|
| End point title | Percentage of Participants With Post-treatment Relapse |
|-----------------|--|

End point description:

Post-treatment relapse was defined as confirmed HCV RNA \geq LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels $<$ LLOQ at the end of treatment.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the end of treatment through 12 weeks after the last dose of study drug

| End point values | Arm A | Arm B | Arm C | Arm D |
|-----------------------------------|--------------------|--------------------|--------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 33 ^[35] | 26 ^[36] | 12 ^[37] | 4 ^[38] |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 3 (0.5 to 15.3) | 0 (0 to 12.9) | 0 (0 to 24.2) | 0 (0 to 49) |

Notes:

[35] - Participants received ≥ 1 dose, completed treatment, had HCV RNA $<$ LLOQ at the final treatment visit

[36] - Participants received ≥ 1 dose, completed treatment, had HCV RNA $<$ LLOQ at the final treatment visit

[37] - Participants received ≥ 1 dose, completed treatment, had HCV RNA $<$ LLOQ at the final treatment visit

[38] - Participants received ≥ 1 dose, completed treatment, had HCV RNA $<$ LLOQ at the final treatment visit

| End point values | Arm E | Arm F | Arm G | Arm H |
|-----------------------------------|-------------------|--------------------|--------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 ^[39] | 21 ^[40] | 12 ^[41] | 6 ^[42] |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 0 (0 to 65.8) | 4.8 (0.8 to 22.7) | 0 (0 to 24.2) | 0 (0 to 39) |

Notes:

[39] - Participants received ≥ 1 dose, completed treatment, had HCV RNA $<$ LLOQ at the final treatment visit

[40] - Participants received ≥ 1 dose, completed treatment, had HCV RNA $<$ LLOQ at the final treatment visit

[41] - Participants received ≥ 1 dose, completed treatment, had HCV RNA $<$ LLOQ at the final treatment visit

[42] - Participants received ≥ 1 dose, completed treatment, had HCV RNA $<$ LLOQ at the final treatment visit

| End point values | Arm I | Arm J | Arm K | |
|------------------|-------|-------|-------|--|
|------------------|-------|-------|-------|--|

| Subject group type | Reporting group | Reporting group | Reporting group | |
|-----------------------------------|-------------------|-------------------|-------------------|--|
| Number of subjects analysed | 3 ^[43] | 2 ^[44] | 1 ^[45] | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 0 (0 to 56.1) | 0 (0 to 65.8) | 0 (0 to 79.3) | |

Notes:

[43] - Participants received ≥ 1 dose, completed treatment, had HCV RNA <LLOQ at the final treatment visit

[44] - Participants received ≥ 1 dose, completed treatment, had HCV RNA <LLOQ at the final treatment visit

[45] - Participants received ≥ 1 dose, completed treatment, had HCV RNA <LLOQ at the final treatment visit

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 30 days after the last dose of study drug (up to 28 weeks).

Adverse event reporting additional description:

TEAEs and SAEs are defined as any AE or SAE with onset or worsening reported by a participant from the time that the first dose of study drug is administered until 30 days after the last dose of study drug. TEAEs and TESAEs were collected whether elicited or spontaneously reported by the participant.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 20.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-------|
| Reporting group title | Arm A |
|-----------------------|-------|

Reporting group description:

Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.

| | |
|-----------------------|-------|
| Reporting group title | Arm B |
|-----------------------|-------|

Reporting group description:

Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.

| | |
|-----------------------|-------|
| Reporting group title | Arm C |
|-----------------------|-------|

Reporting group description:

Liver transplant recipients with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks.

| | |
|-----------------------|-------|
| Reporting group title | Arm D |
|-----------------------|-------|

Reporting group description:

Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks.

| | |
|-----------------------|-------|
| Reporting group title | Arm E |
|-----------------------|-------|

Reporting group description:

Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

| | |
|-----------------------|-------|
| Reporting group title | Arm F |
|-----------------------|-------|

Reporting group description:

Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

| | |
|-----------------------|-------|
| Reporting group title | Arm H |
|-----------------------|-------|

Reporting group description:

Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

| | |
|-----------------------|-------|
| Reporting group title | Arm G |
|-----------------------|-------|

Reporting group description:

Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.

| | |
|---|-------|
| Reporting group title | Arm J |
| Reporting group description: Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks. | |
| Reporting group title | Arm I |
| Reporting group description: Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks. | |
| Reporting group title | Arm K |
| Reporting group description: Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks. | |

| Serious adverse events | Arm A | Arm B | Arm C |
|---|----------------|----------------|----------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Injury, poisoning and procedural complications | | | |
| OVERDOSE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| HYPOTENSION | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| TACHYCARDIA | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| ISCHAEMIC CEREBRAL INFARCTION | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| TRANSIENT ISCHAEMIC ATTACK | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| LEUKOCYTOSIS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| OEDEMA PERIPHERAL | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| NAUSEA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| VOMITING | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| ACUTE RESPIRATORY FAILURE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| ACUTE KIDNEY INJURY | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| PAIN IN EXTREMITY | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| ATYPICAL PNEUMONIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| LOWER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| PNEUMONIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| HYPONATRAEMIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-------|-------|-------|
| Serious adverse events | Arm D | Arm E | Arm F |
| Total subjects affected by serious adverse events | | | |

| | | | |
|--|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 2 / 22 (9.09%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Injury, poisoning and procedural complications | | | |
| OVERDOSE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| HYPOTENSION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| TACHYCARDIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| ISCHAEMIC CEREBRAL INFARCTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| TRANSIENT ISCHAEMIC ATTACK | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| LEUKOCYTOSIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| OEDEMA PERIPHERAL | | | |

| | | | |
|--|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| NAUSEA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| VOMITING | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| ACUTE RESPIRATORY FAILURE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| ACUTE KIDNEY INJURY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| PAIN IN EXTREMITY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| ATYPICAL PNEUMONIA | | | |

| | | | |
|---|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| LOWER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| PNEUMONIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| HYPONATRAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Arm H | Arm G | Arm J |
|---|----------------|----------------|---------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 4 / 9 (44.44%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| number of deaths (all causes) | 1 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Injury, poisoning and procedural complications | | | |
| OVERDOSE | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| HYPOTENSION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| TACHYCARDIA | | | |

| | | | |
|--|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| ISCHAEMIC CEREBRAL INFARCTION | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| TRANSIENT ISCHAEMIC ATTACK | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| LEUKOCYTOSIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| OEDEMA PERIPHERAL | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| NAUSEA | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| VOMITING | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| ACUTE RESPIRATORY FAILURE | | | |

| | | | |
|---|----------------|----------------|---------------|
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| ACUTE KIDNEY INJURY | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| PAIN IN EXTREMITY | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| ATYPICAL PNEUMONIA | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| LOWER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| PNEUMONIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| HYPONATRAEMIA | | | |

| | | | |
|---|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Arm I | Arm K | |
|---|---------------|---------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | | | |
| Injury, poisoning and procedural complications | | | |
| OVERDOSE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| HYPOTENSION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| TACHYCARDIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| ISCHAEMIC CEREBRAL INFARCTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| TRANSIENT ISCHAEMIC ATTACK | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| LEUKOCYTOSIS | | | |

| | | | |
|--|---------------|---------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| OEDEMA PERIPHERAL | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| NAUSEA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| VOMITING | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| ACUTE RESPIRATORY FAILURE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| ACUTE KIDNEY INJURY | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| PAIN IN EXTREMITY | | | |

| | | | |
|---|---------------|---------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| ATYPICAL PNEUMONIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LOWER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PNEUMONIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| HYPONATRAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Arm A | Arm B | Arm C |
|--|------------------|-------------------|------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 33 / 34 (97.06%) | 27 / 27 (100.00%) | 12 / 13 (92.31%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| KERATOACANTHOMA | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| SQUAMOUS CELL CARCINOMA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|--|------------------|------------------|-----------------|
| Vascular disorders | | | |
| HOT FLUSH | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| HYPERTENSION | | | |
| subjects affected / exposed | 3 / 34 (8.82%) | 3 / 27 (11.11%) | 1 / 13 (7.69%) |
| occurrences (all) | 3 | 3 | 1 |
| General disorders and administration site conditions | | | |
| ASTHENIA | | | |
| subjects affected / exposed | 8 / 34 (23.53%) | 7 / 27 (25.93%) | 1 / 13 (7.69%) |
| occurrences (all) | 11 | 13 | 1 |
| CHEST PAIN | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 2 / 27 (7.41%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| CHILLS | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| EXERCISE TOLERANCE DECREASED | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| FACE OEDEMA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| FATIGUE | | | |
| subjects affected / exposed | 17 / 34 (50.00%) | 14 / 27 (51.85%) | 4 / 13 (30.77%) |
| occurrences (all) | 20 | 16 | 4 |
| FEELING ABNORMAL | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| FEELING COLD | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| HERNIA PAIN | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| INFLUENZA LIKE ILLNESS | | | |

| | | | |
|--|-----------------|----------------|----------------|
| subjects affected / exposed | 2 / 34 (5.88%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| NON-CARDIAC CHEST PAIN | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| OEDEMA | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| OEDEMA PERIPHERAL | | | |
| subjects affected / exposed | 5 / 34 (14.71%) | 2 / 27 (7.41%) | 1 / 13 (7.69%) |
| occurrences (all) | 5 | 2 | 1 |
| PAIN | | | |
| subjects affected / exposed | 3 / 34 (8.82%) | 2 / 27 (7.41%) | 0 / 13 (0.00%) |
| occurrences (all) | 3 | 3 | 0 |
| PERIPHERAL SWELLING | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 2 / 27 (7.41%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| PYREXIA | | | |
| subjects affected / exposed | 5 / 34 (14.71%) | 2 / 27 (7.41%) | 0 / 13 (0.00%) |
| occurrences (all) | 7 | 2 | 0 |
| Immune system disorders | | | |
| ALLERGY TO ARTHROPOD BITE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LIVER TRANSPLANT REJECTION | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 0 | 1 |
| SEASONAL ALLERGY | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| ERECTILE DYSFUNCTION | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| GENITAL RASH | | | |

| | | | |
|---|------------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| PENILE BLISTER | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| PROSTATITIS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| PROSTATOMEGALY | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VULVOVAGINAL PRURITUS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| CHOKING | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| COUGH | | | |
| subjects affected / exposed | 11 / 34 (32.35%) | 5 / 27 (18.52%) | 2 / 13 (15.38%) |
| occurrences (all) | 14 | 6 | 3 |
| DRY THROAT | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| DYSPHONIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DYSPNOEA | | | |
| subjects affected / exposed | 3 / 34 (8.82%) | 3 / 27 (11.11%) | 0 / 13 (0.00%) |
| occurrences (all) | 4 | 4 | 0 |
| DYSPNOEA EXERTIONAL | | | |
| subjects affected / exposed | 5 / 34 (14.71%) | 5 / 27 (18.52%) | 0 / 13 (0.00%) |
| occurrences (all) | 5 | 5 | 0 |
| NASAL CONGESTION | | | |

| | | | |
|------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| OROPHARYNGEAL PAIN | | | |
| subjects affected / exposed | 3 / 34 (8.82%) | 1 / 27 (3.70%) | 1 / 13 (7.69%) |
| occurrences (all) | 3 | 1 | 1 |
| PARANASAL SINUS DISCOMFORT | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| PRODUCTIVE COUGH | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 3 | 2 | 0 |
| RESPIRATORY TRACT CONGESTION | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| RHINORRHOEA | | | |
| subjects affected / exposed | 6 / 34 (17.65%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 6 | 0 | 0 |
| SINUS CONGESTION | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 1 / 27 (3.70%) | 1 / 13 (7.69%) |
| occurrences (all) | 2 | 2 | 1 |
| SNEEZING | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| THROAT IRRITATION | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| UPPER RESPIRATORY TRACT CONGESTION | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| UPPER-AIRWAY COUGH SYNDROME | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| WHEEZING | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| Psychiatric disorders | | | |
| ABNORMAL DREAMS | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| AFFECT LABILITY | | | |
| subjects affected / exposed | 3 / 34 (8.82%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| ANXIETY | | | |
| subjects affected / exposed | 5 / 34 (14.71%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| APATHY | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| CONFUSIONAL STATE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DEPRESSED MOOD | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| DEPRESSION | | | |
| subjects affected / exposed | 4 / 34 (11.76%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| EMOTIONAL DISORDER | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| INSOMNIA | | | |
| subjects affected / exposed | 9 / 34 (26.47%) | 3 / 27 (11.11%) | 0 / 13 (0.00%) |
| occurrences (all) | 9 | 3 | 0 |
| IRRITABILITY | | | |
| subjects affected / exposed | 4 / 34 (11.76%) | 2 / 27 (7.41%) | 0 / 13 (0.00%) |
| occurrences (all) | 4 | 2 | 0 |
| LIBIDO INCREASED | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| MANIA | | | |

| | | | |
|--------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| MOOD SWINGS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| NIGHTMARE | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| RESTLESSNESS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 0 | 1 |
| Investigations | | | |
| ALANINE AMINOTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| ASPARTATE AMINOTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD ALKALINE PHOSPHATASE INCREASED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 0 | 1 |
| BLOOD BICARBONATE DECREASED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD BILIRUBIN INCREASED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD CREATININE INCREASED | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 27 (3.70%) | 1 / 13 (7.69%) |
| occurrences (all) | 1 | 1 | 1 |
| BLOOD GLUCOSE INCREASED | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| BLOOD POTASSIUM INCREASED | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD PRESSURE INCREASED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD TRIGLYCERIDES INCREASED | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| BLOOD UREA INCREASED | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| BLOOD URINE PRESENT | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| CARDIAC MURMUR | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| CYTOMEGALOVIRUS TEST POSITIVE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GAMMA-GLUTAMYLTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 0 | 1 |
| HAEMATOCRIT DECREASED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HAEMOGLOBIN DECREASED | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| IMMUNOSUPPRESSANT DRUG LEVEL INCREASED | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| LYMPHOCYTE COUNT DECREASED | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| NEUTROPHIL COUNT DECREASED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VITAMIN D DECREASED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| WEIGHT DECREASED | | | |
| subjects affected / exposed | 3 / 34 (8.82%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| WEIGHT INCREASED | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| WHITE BLOOD CELL COUNT DECREASED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| ACCIDENT | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| ARTHROPOD BITE | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| ARTHROPOD STING | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| CONTUSION | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 1 / 27 (3.70%) | 1 / 13 (7.69%) |
| occurrences (all) | 2 | 1 | 1 |
| EXCORIATION | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FALL | | | |

| | | | |
|------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 2 / 34 (5.88%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 2 | 0 | 1 |
| FEMORAL NECK FRACTURE | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| JOINT INJURY | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LACERATION | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 2 / 27 (7.41%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| MUSCLE STRAIN | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| OVERDOSE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| POST-TRAUMATIC NECK SYNDROME | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| SCRATCH | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| SUNBURN | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| SUPERFICIAL INJURY OF EYE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| TOOTH FRACTURE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TRAUMATIC FRACTURE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 0 | 1 |
| Cardiac disorders | | | |

| | | | |
|-----------------------------|------------------|-----------------|-----------------|
| PALPITATIONS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nervous system disorders | | | |
| BALANCE DISORDER | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CAROTID ARTERY STENOSIS | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| DIZZINESS | | | |
| subjects affected / exposed | 6 / 34 (17.65%) | 4 / 27 (14.81%) | 1 / 13 (7.69%) |
| occurrences (all) | 7 | 4 | 1 |
| DYSGEUSIA | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| HEADACHE | | | |
| subjects affected / exposed | 15 / 34 (44.12%) | 8 / 27 (29.63%) | 2 / 13 (15.38%) |
| occurrences (all) | 20 | 9 | 3 |
| HYPERSONMIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| HYPOAESTHESIA | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| MEMORY IMPAIRMENT | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 1 / 27 (3.70%) | 1 / 13 (7.69%) |
| occurrences (all) | 2 | 1 | 1 |
| MIGRAINE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 1 | 1 |
| ORTHOSTATIC INTOLERANCE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PARAESTHESIA | | | |

| | | | |
|--------------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| POOR QUALITY SLEEP | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| PRESYNCOPE | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| SEIZURE | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| SINUS HEADACHE | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| SYNCOPE | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| TENSION HEADACHE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TREMOR | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| TUNNEL VISION | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| ANAEMIA | | | |
| subjects affected / exposed | 8 / 34 (23.53%) | 8 / 27 (29.63%) | 1 / 13 (7.69%) |
| occurrences (all) | 8 | 9 | 1 |
| HAEMOLYTIC ANAEMIA | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| LEUKOPENIA | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|---------------------|---------------------|----------------------|
| LYMPHOPENIA subjects affected / exposed occurrences (all) | 2 / 34 (5.88%) 2 | 0 / 27 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| Ear and labyrinth disorders | | | |
| EAR PAIN subjects affected / exposed occurrences (all) | 1 / 34 (2.94%) 1 | 0 / 27 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| VERTIGO subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 27 (0.00%) 0 | 2 / 13 (15.38%) 2 |
| Eye disorders | | | |
| DIPLOPIA subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 27 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| DRY EYE subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 27 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| EYE PAIN subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 1 / 27 (3.70%) 1 | 0 / 13 (0.00%) 0 |
| EYE PRURITUS subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 27 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| OCULAR DISCOMFORT subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 1 / 27 (3.70%) 1 | 0 / 13 (0.00%) 0 |
| OCULAR HYPERAEMIA subjects affected / exposed occurrences (all) | 1 / 34 (2.94%) 1 | 0 / 27 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| VISION BLURRED subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 27 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| VISUAL IMPAIRMENT subjects affected / exposed occurrences (all) | 1 / 34 (2.94%) 1 | 0 / 27 (0.00%) 0 | 0 / 13 (0.00%) 0 |
| VITREOUS FLOATERS | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastrointestinal disorders | | | |
| ABDOMINAL DISCOMFORT | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| ABDOMINAL DISTENSION | | | |
| subjects affected / exposed | 3 / 34 (8.82%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| ABDOMINAL PAIN | | | |
| subjects affected / exposed | 5 / 34 (14.71%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 5 | 0 | 1 |
| ABDOMINAL PAIN LOWER | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| ABDOMINAL PAIN UPPER | | | |
| subjects affected / exposed | 4 / 34 (11.76%) | 2 / 27 (7.41%) | 1 / 13 (7.69%) |
| occurrences (all) | 4 | 2 | 1 |
| ANAL PRURITUS | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| ANORECTAL DISCOMFORT | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| APHTHOUS ULCER | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| BOWEL MOVEMENT IRREGULARITY | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| CONSTIPATION | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 1 / 27 (3.70%) | 1 / 13 (7.69%) |
| occurrences (all) | 2 | 1 | 1 |
| DENTAL CARIES | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |

| | | | |
|----------------------------------|-----------------|-----------------|----------------|
| DIARRHOEA | | | |
| subjects affected / exposed | 9 / 34 (26.47%) | 6 / 27 (22.22%) | 1 / 13 (7.69%) |
| occurrences (all) | 17 | 7 | 1 |
| DIVERTICULUM INTESTINAL | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DRY MOUTH | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| DYSPEPSIA | | | |
| subjects affected / exposed | 3 / 34 (8.82%) | 1 / 27 (3.70%) | 1 / 13 (7.69%) |
| occurrences (all) | 3 | 2 | 1 |
| DYSPHAGIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| EPIGASTRIC DISCOMFORT | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FAECES DISCOLOURED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| FLATULENCE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GASTROOESOPHAGEAL REFLUX DISEASE | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| GINGIVAL BLEEDING | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| HAEMORRHOIDS | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| LIP DRY | | | |

| | | | |
|--|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| NAUSEA | | | |
| subjects affected / exposed | 8 / 34 (23.53%) | 11 / 27 (40.74%) | 2 / 13 (15.38%) |
| occurrences (all) | 9 | 14 | 2 |
| OESOPHAGEAL DILATATION | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SMALL INTESTINAL OBSTRUCTION | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TOOTH IMPACTED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TOOTHACHE | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| VOMITING | | | |
| subjects affected / exposed | 4 / 34 (11.76%) | 5 / 27 (18.52%) | 0 / 13 (0.00%) |
| occurrences (all) | 6 | 8 | 0 |
| Hepatobiliary disorders | | | |
| HYPERBILIRUBINAEMIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| JAUNDICE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 3 / 27 (11.11%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 6 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| ACNE | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| ALOPECIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 2 / 27 (7.41%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| DERMATITIS CONTACT | | | |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| DRY SKIN | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| ERYTHEMA | | | |
| subjects affected / exposed | 3 / 34 (8.82%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| HAIR GROWTH ABNORMAL | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| HYPERHIDROSIS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PETECHIAE | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| PHOTOSENSITIVITY REACTION | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| PRURITUS | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 4 / 27 (14.81%) | 1 / 13 (7.69%) |
| occurrences (all) | 2 | 6 | 1 |
| PRURITUS GENERALISED | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| PSORIASIS | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| RASH | | | |
| subjects affected / exposed | 7 / 34 (20.59%) | 9 / 27 (33.33%) | 0 / 13 (0.00%) |
| occurrences (all) | 10 | 12 | 0 |
| RASH GENERALISED | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RASH MACULAR | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| RASH MACULO-PAPULAR | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RASH PAPULAR | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| RASH PRURITIC | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| SKIN EXFOLIATION | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| SKIN LESION | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 2 / 27 (7.41%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| SKIN TIGHTNESS | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| URTICARIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Renal and urinary disorders | | | |
| ANURIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CHROMATURIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DYSURIA | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| POLLAKIURIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | | |
|---|-----------------------------|-----------------|----------------|----------------|
| POLYURIA | subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| | occurrences (all) | 1 | 0 | 0 |
| | | | | |
| PROTEINURIA | subjects affected / exposed | 2 / 34 (5.88%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| | occurrences (all) | 2 | 0 | 0 |
| | | | | |
| URINARY RETENTION | subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| | occurrences (all) | 0 | 0 | 0 |
| | | | | |
| Musculoskeletal and connective tissue disorders | | | | |
| ARTHRALGIA | subjects affected / exposed | 2 / 34 (5.88%) | 2 / 27 (7.41%) | 0 / 13 (0.00%) |
| | occurrences (all) | 2 | 2 | 0 |
| | | | | |
| ARTHRITIS | subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| | occurrences (all) | 1 | 0 | 0 |
| | | | | |
| BACK PAIN | subjects affected / exposed | 6 / 34 (17.65%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| | occurrences (all) | 7 | 0 | 1 |
| | | | | |
| FLANK PAIN | subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| | occurrences (all) | 1 | 0 | 0 |
| | | | | |
| GOUTY ARTHRITIS | subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| | occurrences (all) | 0 | 0 | 1 |
| | | | | |
| GROIN PAIN | subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| | occurrences (all) | 0 | 0 | 0 |
| | | | | |
| LIMB DISCOMFORT | subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| | occurrences (all) | 1 | 0 | 0 |
| | | | | |
| MUSCLE FATIGUE | subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| | occurrences (all) | 1 | 0 | 0 |
| | | | | |
| MUSCLE SPASMS | | | | |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 7 / 34 (20.59%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 8 | 1 | 0 |
| MUSCLE TWITCHING | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MUSCULOSKELETAL CHEST PAIN | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 0 | 1 |
| MUSCULOSKELETAL DISCOMFORT | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MYALGIA | | | |
| subjects affected / exposed | 3 / 34 (8.82%) | 4 / 27 (14.81%) | 0 / 13 (0.00%) |
| occurrences (all) | 4 | 4 | 0 |
| NECK PAIN | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| PAIN IN EXTREMITY | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| TENDONITIS | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Infections and infestations | | | |
| ACARODERMATITIS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CELLULITIS | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| CYTOMEGALOVIRUS VIRAEMIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FOLLICULITIS | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| FUNGAL INFECTION | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| GASTROENTERITIS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 0 | 1 |
| HERPES ZOSTER | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| HORDEOLUM | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| IMPETIGO | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| INFLUENZA | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| LOCALISED INFECTION | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ORAL CANDIDIASIS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ORAL HERPES | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| OTITIS MEDIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 0 | 1 |
| PHARYNGITIS | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| PHARYNGITIS STREPTOCOCCAL | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| SINUSITIS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| SKIN INFECTION | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| TINEA CRURIS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TINEA PEDIS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TOOTH INFECTION | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| UPPER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| URINARY TRACT INFECTION | | | |
| subjects affected / exposed | 4 / 34 (11.76%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 5 | 1 | 0 |
| VIRAL UPPER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 3 / 34 (8.82%) | 2 / 27 (7.41%) | 2 / 13 (15.38%) |
| occurrences (all) | 3 | 2 | 2 |
| Metabolism and nutrition disorders | | | |
| DECREASED APPETITE | | | |
| subjects affected / exposed | 4 / 34 (11.76%) | 3 / 27 (11.11%) | 1 / 13 (7.69%) |
| occurrences (all) | 5 | 3 | 1 |
| DEHYDRATION | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DIABETES MELLITUS | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| DIABETES MELLITUS INADEQUATE CONTROL | | | |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GOUT | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 1 | 2 |
| HYPERGLYCAEMIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 27 (3.70%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| HYPERKALAEMIA | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 0 / 27 (0.00%) | 2 / 13 (15.38%) |
| occurrences (all) | 2 | 0 | 2 |
| HYPERURICAEMIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPOGLYCAEMIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPOKALAEMIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPOMAGNESAEMIA | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 27 (0.00%) | 0 / 13 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| HYPONATRAEMIA | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 27 (0.00%) | 1 / 13 (7.69%) |
| occurrences (all) | 0 | 0 | 1 |

| Non-serious adverse events | Arm D | Arm E | Arm F |
|---|-----------------|-----------------|-------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 4 / 4 (100.00%) | 2 / 2 (100.00%) | 22 / 22 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| KERATOACANTHOMA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SQUAMOUS CELL CARCINOMA | | | |

| | | | |
|---|--------------------|--------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 4 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 22 (0.00%) 0 |
| Vascular disorders | | | |
| HOT FLUSH | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPERTENSION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| ASTHENIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 2 / 2 (100.00%) | 2 / 22 (9.09%) |
| occurrences (all) | 0 | 3 | 2 |
| CHEST PAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CHILLS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| EXERCISE TOLERANCE DECREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FACE OEDEMA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FATIGUE | | | |
| subjects affected / exposed | 4 / 4 (100.00%) | 0 / 2 (0.00%) | 14 / 22 (63.64%) |
| occurrences (all) | 8 | 0 | 14 |
| FEELING ABNORMAL | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FEELING COLD | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HERNIA PAIN | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| INFLUENZA LIKE ILLNESS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| NON-CARDIAC CHEST PAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| OEDEMA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| OEDEMA PERIPHERAL | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 1 / 2 (50.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 2 | 1 | 1 |
| PAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| PERIPHERAL SWELLING | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PYREXIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| ALLERGY TO ARTHROPOD BITE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| LIVER TRANSPLANT REJECTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SEASONAL ALLERGY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |

| | | | |
|---|----------------|----------------|-----------------|
| ERECTILE DYSFUNCTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GENITAL RASH | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PENILE BLISTER | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PROSTATITIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PROSTATOMEGALY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VULVOVAGINAL PRURITUS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| CHOKING | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| COUGH | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 2 (50.00%) | 3 / 22 (13.64%) |
| occurrences (all) | 0 | 1 | 3 |
| DRY THROAT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DYSPHONIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| DYSPNOEA | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 2 / 22 (9.09%) |
| occurrences (all) | 3 | 0 | 6 |
| DYSPNOEA EXERTIONAL | | | |

| | | | |
|------------------------------------|---------------|---------------|-----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| NASAL CONGESTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| OROPHARYNGEAL PAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 3 / 22 (13.64%) |
| occurrences (all) | 0 | 0 | 4 |
| PARANASAL SINUS DISCOMFORT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PRODUCTIVE COUGH | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 3 / 22 (13.64%) |
| occurrences (all) | 0 | 0 | 3 |
| RESPIRATORY TRACT CONGESTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RHINORRHOEA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| SINUS CONGESTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SNEEZING | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| THROAT IRRITATION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| UPPER RESPIRATORY TRACT CONGESTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| UPPER-AIRWAY COUGH SYNDROME | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| WHEEZING | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| ABNORMAL DREAMS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| AFFECT LABILITY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ANXIETY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| APATHY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CONFUSIONAL STATE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DEPRESSED MOOD | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DEPRESSION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| EMOTIONAL DISORDER | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| INSOMNIA | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 1 / 2 (50.00%) | 3 / 22 (13.64%) |
| occurrences (all) | 1 | 1 | 3 |
| IRRITABILITY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LIBIDO INCREASED | | | |

| | | | |
|--------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MANIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MOOD SWINGS | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 1 | 0 | 1 |
| NIGHTMARE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RESTLESSNESS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| ALANINE AMINOTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| ASPARTATE AMINOTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| BLOOD ALKALINE PHOSPHATASE INCREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD BICARBONATE DECREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD BILIRUBIN INCREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 2 |
| BLOOD CREATININE INCREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD GLUCOSE INCREASED | | | |

| | | | |
|--|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD POTASSIUM INCREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| BLOOD PRESSURE INCREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD TRIGLYCERIDES INCREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD UREA INCREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD URINE PRESENT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CARDIAC MURMUR | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| CYTOMEGALOVIRUS TEST POSITIVE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GAMMA-GLUTAMYLTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HAEMATOCRIT DECREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HAEMOGLOBIN DECREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 2 / 22 (9.09%) |
| occurrences (all) | 0 | 0 | 2 |
| IMMUNOSUPPRESSANT DRUG LEVEL INCREASED | | | |

| | | | |
|--|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LYMPHOCYTE COUNT DECREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| NEUTROPHIL COUNT DECREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VITAMIN D DECREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| WEIGHT DECREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| WEIGHT INCREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| WHITE BLOOD CELL COUNT DECREASED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| ACCIDENT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ARTHROPOD BITE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| ARTHROPOD STING | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CONTUSION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| EXCORIATION | | | |

| | | | |
|------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| FALL | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FEMORAL NECK FRACTURE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| JOINT INJURY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LACERATION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| MUSCLE STRAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| OVERDOSE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| POST-TRAUMATIC NECK SYNDROME | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SCRATCH | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SUNBURN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SUPERFICIAL INJURY OF EYE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TOOTH FRACTURE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| TRAUMATIC FRACTURE | | | |

| | | | |
|--|---------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 4 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 22 (0.00%) 0 |
| Cardiac disorders PALPITATIONS subjects affected / exposed occurrences (all) | 1 / 4 (25.00%) 1 | 0 / 2 (0.00%) 0 | 0 / 22 (0.00%) 0 |
| Nervous system disorders BALANCE DISORDER subjects affected / exposed occurrences (all) | 0 / 4 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 22 (0.00%) 0 |
| CAROTID ARTERY STENOSIS subjects affected / exposed occurrences (all) | 0 / 4 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 22 (0.00%) 0 |
| DIZZINESS subjects affected / exposed occurrences (all) | 1 / 4 (25.00%) 1 | 1 / 2 (50.00%) 1 | 4 / 22 (18.18%) 4 |
| DYSGEUSIA subjects affected / exposed occurrences (all) | 0 / 4 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 22 (0.00%) 0 |
| HEADACHE subjects affected / exposed occurrences (all) | 2 / 4 (50.00%) 3 | 1 / 2 (50.00%) 2 | 6 / 22 (27.27%) 6 |
| HYPERSOMNIA subjects affected / exposed occurrences (all) | 0 / 4 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 22 (0.00%) 0 |
| HYPOAESTHESIA subjects affected / exposed occurrences (all) | 1 / 4 (25.00%) 1 | 0 / 2 (0.00%) 0 | 0 / 22 (0.00%) 0 |
| MEMORY IMPAIRMENT subjects affected / exposed occurrences (all) | 0 / 4 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 22 (0.00%) 0 |
| MIGRAINE subjects affected / exposed occurrences (all) | 0 / 4 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 22 (0.00%) 0 |
| ORTHOSTATIC INTOLERANCE | | | |

| | | | |
|--------------------------------------|----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PARAESTHESIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| POOR QUALITY SLEEP | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PRESYNCOPE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SEIZURE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SINUS HEADACHE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SYNCOPE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TENSION HEADACHE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| TREMOR | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TUNNEL VISION | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| ANAEMIA | | | |
| subjects affected / exposed | 3 / 4 (75.00%) | 2 / 2 (100.00%) | 4 / 22 (18.18%) |
| occurrences (all) | 3 | 3 | 4 |
| HAEMOLYTIC ANAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| LEUKOPENIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| LYMPHOPENIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| EAR PAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VERTIGO | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| DIPLOPIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DRY EYE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 2 (50.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| EYE PAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| EYE PRURITUS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 2 (50.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| OCULAR DISCOMFORT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| OCULAR HYPERAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VISION BLURRED | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| VISUAL IMPAIRMENT | | | |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VITREOUS FLOATERS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| ABDOMINAL DISCOMFORT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 3 / 22 (13.64%) |
| occurrences (all) | 0 | 0 | 3 |
| ABDOMINAL DISTENSION | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 1 | 0 | 1 |
| ABDOMINAL PAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 2 (50.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| ABDOMINAL PAIN LOWER | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| ABDOMINAL PAIN UPPER | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ANAL PRURITUS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ANORECTAL DISCOMFORT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| APHTHOUS ULCER | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BOWEL MOVEMENT IRREGULARITY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CONSTIPATION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 4 / 22 (18.18%) |
| occurrences (all) | 0 | 0 | 4 |

| | | | |
|----------------------------------|----------------|----------------|-----------------|
| DENTAL CARIES | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DIARRHOEA | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 1 / 2 (50.00%) | 6 / 22 (27.27%) |
| occurrences (all) | 1 | 1 | 6 |
| DIVERTICULUM INTESTINAL | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| DRY MOUTH | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| DYSPEPSIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| DYSPHAGIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| EPIGASTRIC DISCOMFORT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FAECES DISCOLOURED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FLATULENCE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| GASTROOESOPHAGEAL REFLUX DISEASE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GINGIVAL BLEEDING | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HAEMORRHOIDS | | | |

| | | | |
|--|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LIP DRY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| NAUSEA | | | |
| subjects affected / exposed | 2 / 4 (50.00%) | 1 / 2 (50.00%) | 4 / 22 (18.18%) |
| occurrences (all) | 2 | 1 | 4 |
| OESOPHAGEAL DILATATION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SMALL INTESTINAL OBSTRUCTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TOOTH IMPACTED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TOOTHACHE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VOMITING | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 1 | 0 | 1 |
| Hepatobiliary disorders | | | |
| HYPERBILIRUBINAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| JAUNDICE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin and subcutaneous tissue disorders | | | |
| ACNE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ALOPECIA | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DERMATITIS CONTACT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DRY SKIN | | | |
| subjects affected / exposed | 2 / 4 (50.00%) | 1 / 2 (50.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 4 | 1 | 1 |
| ERYTHEMA | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| HAIR GROWTH ABNORMAL | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPERHIDROSIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| PETECHIAE | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PHOTOSENSITIVITY REACTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PRURITUS | | | |
| subjects affected / exposed | 4 / 4 (100.00%) | 2 / 2 (100.00%) | 5 / 22 (22.73%) |
| occurrences (all) | 8 | 4 | 5 |
| PRURITUS GENERALISED | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PSORIASIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RASH | | | |
| subjects affected / exposed | 2 / 4 (50.00%) | 0 / 2 (0.00%) | 4 / 22 (18.18%) |
| occurrences (all) | 4 | 0 | 4 |
| RASH GENERALISED | | | |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| RASH MACULAR | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RASH MACULO-PAPULAR | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| RASH PAPULAR | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RASH PRURITIC | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| SKIN EXFOLIATION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SKIN LESION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SKIN TIGHTNESS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| URTICARIA | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Renal and urinary disorders | | | |
| ANURIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CHROMATURIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DYSURIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|----------------|---------------|----------------|
| POLLAKIURIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| POLYURIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PROTEINURIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| URINARY RETENTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| ARTHRALGIA | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| ARTHRITIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BACK PAIN | | | |
| subjects affected / exposed | 2 / 4 (50.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 2 | 0 | 1 |
| FLANK PAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GOUTY ARTHRITIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GROIN PAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LIMB DISCOMFORT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MUSCLE FATIGUE | | | |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MUSCLE SPASMS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MUSCLE TWITCHING | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MUSCULOSKELETAL CHEST PAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MUSCULOSKELETAL DISCOMFORT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| MYALGIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| NECK PAIN | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 1 / 2 (50.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| PAIN IN EXTREMITY | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TENDONITIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| ACARODERMATITIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| CELLULITIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CYTOMEGALOVIRUS VIRAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| FOLLICULITIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FUNGAL INFECTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GASTROENTERITIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HERPES ZOSTER | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HORDEOLUM | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| IMPETIGO | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| INFLUENZA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| LOCALISED INFECTION | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| ORAL CANDIDIASIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| ORAL HERPES | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| OTITIS MEDIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PHARYNGITIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|----------------|----------------|----------------|
| PHARYNGITIS STREPTOCOCCAL | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SINUSITIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SKIN INFECTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TINEA CRURIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TINEA PEDIS | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TOOTH INFECTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| UPPER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| URINARY TRACT INFECTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VIRAL UPPER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| DECREASED APPETITE | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | 1 / 2 (50.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| DEHYDRATION | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DIABETES MELLITUS | | | |

| | | | |
|--------------------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| DIABETES MELLITUS INADEQUATE CONTROL | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| GOUT | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPERGLYCAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| HYPERKALAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| HYPERURICAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all) | 0 | 0 | 1 |
| HYPOGLYCAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPOKALAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPOMAGNESAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPONATRAEMIA | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | 0 / 2 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | Arm H | Arm G | Arm J |
|---|----------------|-------------------|-----------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 8 / 9 (88.89%) | 12 / 12 (100.00%) | 2 / 2 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|--|----------------|-----------------|----------------|
| KERATOACANTHOMA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SQUAMOUS CELL CARCINOMA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular disorders | | | |
| HOT FLUSH | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPERTENSION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| ASTHENIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| CHEST PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CHILLS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| EXERCISE TOLERANCE DECREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FACE OEDEMA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FATIGUE | | | |
| subjects affected / exposed | 6 / 9 (66.67%) | 2 / 12 (16.67%) | 1 / 2 (50.00%) |
| occurrences (all) | 6 | 2 | 1 |
| FEELING ABNORMAL | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FEELING COLD | | | |

| | | | |
|-----------------------------|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HERNIA PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| INFLUENZA LIKE ILLNESS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| NON-CARDIAC CHEST PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| OEDEMA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| OEDEMA PERIPHERAL | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| PERIPHERAL SWELLING | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| PYREXIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Immune system disorders | | | |
| ALLERGY TO ARTHROPOD BITE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LIVER TRANSPLANT REJECTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SEASONAL ALLERGY | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|----------------|----------------|----------------|
| Reproductive system and breast disorders | | | |
| ERECTILE DYSFUNCTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GENITAL RASH | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PENILE BLISTER | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PROSTATITIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PROSTATOMEGALY | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| VULVOVAGINAL PRURITUS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| CHOKING | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| COUGH | | | |
| subjects affected / exposed | 3 / 9 (33.33%) | 1 / 12 (8.33%) | 1 / 2 (50.00%) |
| occurrences (all) | 3 | 1 | 1 |
| DRY THROAT | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DYSPHONIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DYSPNOEA | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| DYSPNOEA EXERTIONAL | | | |

| | | | |
|------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| NASAL CONGESTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| OROPHARYNGEAL PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| PARANASAL SINUS DISCOMFORT | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PRODUCTIVE COUGH | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RESPIRATORY TRACT CONGESTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RHINORRHOEA | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 1 | 0 | 1 |
| SINUS CONGESTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| SNEEZING | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| THROAT IRRITATION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| UPPER RESPIRATORY TRACT CONGESTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| UPPER-AIRWAY COUGH SYNDROME | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|-----------------|----------------|
| WHEEZING | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| ABNORMAL DREAMS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| AFFECT LABILITY | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ANXIETY | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| APATHY | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CONFUSIONAL STATE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| DEPRESSED MOOD | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| DEPRESSION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| EMOTIONAL DISORDER | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| INSOMNIA | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 2 / 12 (16.67%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| IRRITABILITY | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 1 | 1 |
| LIBIDO INCREASED | | | |

| | | | |
|--------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MANIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MOOD SWINGS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| NIGHTMARE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RESTLESSNESS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| ALANINE AMINOTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ASPARTATE AMINOTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD ALKALINE PHOSPHATASE INCREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD BICARBONATE DECREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| BLOOD BILIRUBIN INCREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD CREATININE INCREASED | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| BLOOD GLUCOSE INCREASED | | | |

| | | | |
|--|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD POTASSIUM INCREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD PRESSURE INCREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| BLOOD TRIGLYCERIDES INCREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD UREA INCREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BLOOD URINE PRESENT | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CARDIAC MURMUR | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CYTOMEGALOVIRUS TEST POSITIVE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| GAMMA-GLUTAMYLTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HAEMATOCRIT DECREASED | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| HAEMOGLOBIN DECREASED | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| IMMUNOSUPPRESSANT DRUG LEVEL INCREASED | | | |

| | | | |
|--|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LYMPHOCYTE COUNT DECREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| NEUTROPHIL COUNT DECREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| VITAMIN D DECREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| WEIGHT DECREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| WEIGHT INCREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| WHITE BLOOD CELL COUNT DECREASED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injury, poisoning and procedural complications | | | |
| ACCIDENT | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ARTHROPOD BITE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ARTHROPOD STING | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CONTUSION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| EXCORIATION | | | |

| | | | |
|------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FALL | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FEMORAL NECK FRACTURE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| JOINT INJURY | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| LACERATION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MUSCLE STRAIN | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| OVERDOSE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| POST-TRAUMATIC NECK SYNDROME | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SCRATCH | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SUNBURN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SUPERFICIAL INJURY OF EYE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TOOTH FRACTURE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TRAUMATIC FRACTURE | | | |

| | | | |
|--|---------------------|----------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Cardiac disorders PALPITATIONS subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 12 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Nervous system disorders BALANCE DISORDER subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 1 / 12 (8.33%) 1 | 0 / 2 (0.00%) 0 |
| CAROTID ARTERY STENOSIS subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| DIZZINESS subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 2 / 12 (16.67%) 2 | 0 / 2 (0.00%) 0 |
| DYSGEUSIA subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| HEADACHE subjects affected / exposed occurrences (all) | 3 / 9 (33.33%) 4 | 6 / 12 (50.00%) 7 | 0 / 2 (0.00%) 0 |
| HYPERSOMNIA subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| HYPOAESTHESIA subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| MEMORY IMPAIRMENT subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| MIGRAINE subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| ORTHOSTATIC INTOLERANCE | | | |

| | | | |
|--------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| PARAESTHESIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| POOR QUALITY SLEEP | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PRESYNCOPE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| SEIZURE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SINUS HEADACHE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SYNCOPE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TENSION HEADACHE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TREMOR | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TUNNEL VISION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| ANAEMIA | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| HAEMOLYTIC ANAEMIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|---------------|----------------|---------------|
| LEUKOPENIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LYMPHOPENIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| EAR PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VERTIGO | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| DIPLOPIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| DRY EYE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| EYE PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| EYE PRURITUS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| OCULAR DISCOMFORT | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| OCULAR HYPERAEMIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VISION BLURRED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| VISUAL IMPAIRMENT | | | |

| | | | |
|-----------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VITREOUS FLOATERS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| ABDOMINAL DISCOMFORT | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| ABDOMINAL DISTENSION | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| ABDOMINAL PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 2 / 12 (16.67%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| ABDOMINAL PAIN LOWER | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| ABDOMINAL PAIN UPPER | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| ANAL PRURITUS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ANORECTAL DISCOMFORT | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| APHTHOUS ULCER | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| BOWEL MOVEMENT IRREGULARITY | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CONSTIPATION | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |

| | | | |
|----------------------------------|----------------|-----------------|----------------|
| DENTAL CARIES | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DIARRHOEA | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 2 / 12 (16.67%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| DIVERTICULUM INTESTINAL | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DRY MOUTH | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| DYSPEPSIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DYSPHAGIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| EPIGASTRIC DISCOMFORT | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| FAECES DISCOLOURED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FLATULENCE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GASTROOESOPHAGEAL REFLUX DISEASE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GINGIVAL BLEEDING | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HAEMORRHOIDS | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LIP DRY | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| NAUSEA | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| OESOPHAGEAL DILATATION | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| SMALL INTESTINAL OBSTRUCTION | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| TOOTH IMPACTED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| TOOTHACHE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| VOMITING | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 1 | 1 |
| Hepatobiliary disorders | | | |
| HYPERBILIRUBINAEMIA | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| JAUNDICE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| ACNE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ALOPECIA | | | |

| | | | |
|-----------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DERMATITIS CONTACT | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DRY SKIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ERYTHEMA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HAIR GROWTH ABNORMAL | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPERHIDROSIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PETECHIAE | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PHOTOSENSITIVITY REACTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PRURITUS | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 4 / 12 (33.33%) | 1 / 2 (50.00%) |
| occurrences (all) | 2 | 4 | 1 |
| PRURITUS GENERALISED | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| PSORIASIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RASH | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| RASH GENERALISED | | | |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RASH MACULAR | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RASH MACULO-PAPULAR | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RASH PAPULAR | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| RASH PRURITIC | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SKIN EXFOLIATION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SKIN LESION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| SKIN TIGHTNESS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| URTICARIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| ANURIA | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| CHROMATURIA | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| DYSURIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|----------------|----------------|---------------|
| POLLAKIURIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| POLYURIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PROTEINURIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| URINARY RETENTION | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| ARTHRALGIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| ARTHRITIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| BACK PAIN | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| FLANK PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GOUTY ARTHRITIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GROIN PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| LIMB DISCOMFORT | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MUSCLE FATIGUE | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MUSCLE SPASMS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| MUSCLE TWITCHING | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| MUSCULOSKELETAL CHEST PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MUSCULOSKELETAL DISCOMFORT | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| MYALGIA | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 12 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 2 | 0 | 1 |
| NECK PAIN | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PAIN IN EXTREMITY | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TENDONITIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| ACARODERMATITIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| CELLULITIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| CYTOMEGALOVIRUS VIRAEMIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|---------------|----------------|---------------|
| FOLLICULITIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| FUNGAL INFECTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GASTROENTERITIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HERPES ZOSTER | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HORDEOLUM | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| IMPETIGO | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| INFLUENZA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| LOCALISED INFECTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ORAL CANDIDIASIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ORAL HERPES | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| OTITIS MEDIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| PHARYNGITIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|----------------|----------------|----------------|
| PHARYNGITIS STREPTOCOCCAL | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SINUSITIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SKIN INFECTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| TINEA CRURIS | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| TINEA PEDIS | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| TOOTH INFECTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| UPPER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| URINARY TRACT INFECTION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| VIRAL UPPER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| DECREASED APPETITE | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| DEHYDRATION | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| DIABETES MELLITUS | | | |

| | | | |
|--------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| DIABETES MELLITUS INADEQUATE CONTROL | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| GOUT | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPERGLYCAEMIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPERKALAEMIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPERURICAEMIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| HYPOGLYCAEMIA | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| HYPOKALAEMIA | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 12 (8.33%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| HYPOMAGNESAEMIA | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| HYPONATRAEMIA | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 12 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |

| Non-serious adverse events | Arm I | Arm K | |
|---|-----------------|-----------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 3 / 3 (100.00%) | 1 / 1 (100.00%) | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|--|----------------|-----------------|--|
| KERATOACANTHOMA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SQUAMOUS CELL CARCINOMA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Vascular disorders | | | |
| HOT FLUSH | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HYPERTENSION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| General disorders and administration site conditions | | | |
| ASTHENIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| CHEST PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| CHILLS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| EXERCISE TOLERANCE DECREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| FACE OEDEMA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| FATIGUE | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 1 (100.00%) | |
| occurrences (all) | 1 | 1 | |
| FEELING ABNORMAL | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| FEELING COLD | | | |

| | | | |
|-----------------------------------|----------------|-----------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HERNIA PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| INFLUENZA LIKE ILLNESS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | |
| occurrences (all) | 0 | 1 | |
| NON-CARDIAC CHEST PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| OEDEMA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| OEDEMA PERIPHERAL | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PERIPHERAL SWELLING | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PYREXIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Immune system disorders | | | |
| ALLERGY TO ARTHROPOD BITE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| LIVER TRANSPLANT REJECTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SEASONAL ALLERGY | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |

| | | | |
|---|---------------|---------------|--|
| Reproductive system and breast disorders | | | |
| ERECTILE DYSFUNCTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| GENITAL RASH | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PENILE BLISTER | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PROSTATITIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PROSTATOMEGALY | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| VULVOVAGINAL PRURITUS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| CHOKING | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| COUGH | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DRY THROAT | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DYSPHONIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DYSPNOEA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DYSPNOEA EXERTIONAL | | | |

| | | | |
|------------------------------------|---------------|---------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| NASAL CONGESTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| OROPHARYNGEAL PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PARANASAL SINUS DISCOMFORT | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PRODUCTIVE COUGH | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| RESPIRATORY TRACT CONGESTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| RHINORRHOEA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SINUS CONGESTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SNEEZING | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| THROAT IRRITATION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| UPPER RESPIRATORY TRACT CONGESTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| UPPER-AIRWAY COUGH SYNDROME | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |

| | | | |
|-----------------------------|---------------|---------------|--|
| WHEEZING | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Psychiatric disorders | | | |
| ABNORMAL DREAMS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| AFFECT LABILITY | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ANXIETY | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| APATHY | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| CONFUSIONAL STATE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DEPRESSED MOOD | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DEPRESSION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| EMOTIONAL DISORDER | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| INSOMNIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| IRRITABILITY | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| LIBIDO INCREASED | | | |

| | | | |
|--------------------------------------|---------------|---------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| MANIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| MOOD SWINGS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| NIGHTMARE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| RESTLESSNESS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Investigations | | | |
| ALANINE AMINOTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ASPARTATE AMINOTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BLOOD ALKALINE PHOSPHATASE INCREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BLOOD BICARBONATE DECREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BLOOD BILIRUBIN INCREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BLOOD CREATININE INCREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BLOOD GLUCOSE INCREASED | | | |

| | | | |
|--|---------------|---------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BLOOD POTASSIUM INCREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BLOOD PRESSURE INCREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BLOOD TRIGLYCERIDES INCREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BLOOD UREA INCREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BLOOD URINE PRESENT | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| CARDIAC MURMUR | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| CYTOMEGALOVIRUS TEST POSITIVE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| GAMMA-GLUTAMYLTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HAEMATOCRIT DECREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HAEMOGLOBIN DECREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| IMMUNOSUPPRESSANT DRUG LEVEL INCREASED | | | |

| | | | |
|--|---------------|---------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| LYMPHOCYTE COUNT DECREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| NEUTROPHIL COUNT DECREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| VITAMIN D DECREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| WEIGHT DECREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| WEIGHT INCREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| WHITE BLOOD CELL COUNT DECREASED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Injury, poisoning and procedural complications | | | |
| ACCIDENT | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ARTHROPOD BITE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ARTHROPOD STING | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| CONTUSION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| EXCORIATION | | | |

| | | | |
|------------------------------|---------------|---------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| FALL | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| FEMORAL NECK FRACTURE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| JOINT INJURY | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| LACERATION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| MUSCLE STRAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| OVERDOSE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| POST-TRAUMATIC NECK SYNDROME | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SCRATCH | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SUNBURN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SUPERFICIAL INJURY OF EYE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| TOOTH FRACTURE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| TRAUMATIC FRACTURE | | | |

| | | | |
|--|--------------------|--------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| Cardiac disorders PALPITATIONS subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| Nervous system disorders BALANCE DISORDER subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| CAROTID ARTERY STENOSIS subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| DIZZINESS subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| DYSGEUSIA subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| HEADACHE subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| HYPERSOMNIA subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| HYPOAESTHESIA subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| MEMORY IMPAIRMENT subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| MIGRAINE subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 0 / 1 (0.00%) 0 | |
| ORTHOSTATIC INTOLERANCE | | | |

| | | | |
|--------------------------------------|----------------|---------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PARAESTHESIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| POOR QUALITY SLEEP | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PRESYNCOPE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SEIZURE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SINUS HEADACHE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SYNCOPE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| TENSION HEADACHE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| TREMOR | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| TUNNEL VISION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Blood and lymphatic system disorders | | | |
| ANAEMIA | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| HAEMOLYTIC ANAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |

| | | | |
|-----------------------------|---------------|---------------|--|
| LEUKOPENIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| LYMPHOPENIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Ear and labyrinth disorders | | | |
| EAR PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| VERTIGO | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Eye disorders | | | |
| DIPLOPIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DRY EYE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| EYE PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| EYE PRURITUS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| OCULAR DISCOMFORT | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| OCULAR HYPERAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| VISION BLURRED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| VISUAL IMPAIRMENT | | | |

| | | | |
|-----------------------------|---------------|-----------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| VITREOUS FLOATERS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Gastrointestinal disorders | | | |
| ABDOMINAL DISCOMFORT | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ABDOMINAL DISTENSION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ABDOMINAL PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ABDOMINAL PAIN LOWER | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ABDOMINAL PAIN UPPER | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ANAL PRURITUS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ANORECTAL DISCOMFORT | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| APHTHOUS ULCER | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BOWEL MOVEMENT IRREGULARITY | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| CONSTIPATION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|----------------------------------|---------------|---------------|--|
| DENTAL CARIES | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DIARRHOEA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DIVERTICULUM INTESTINAL | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DRY MOUTH | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DYSPEPSIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DYSPHAGIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| EPIGASTRIC DISCOMFORT | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| FAECES DISCOLOURED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| FLATULENCE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| GASTROOESOPHAGEAL REFLUX DISEASE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| GINGIVAL BLEEDING | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HAEMORRHOIDS | | | |

| | | | |
|--|----------------|-----------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| LIP DRY | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| NAUSEA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| OESOPHAGEAL DILATATION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SMALL INTESTINAL OBSTRUCTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| TOOTH IMPACTED | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| TOOTHACHE | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| VOMITING | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hepatobiliary disorders | | | |
| HYPERBILIRUBINAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| JAUNDICE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) | |
| occurrences (all) | 0 | 1 | |
| Skin and subcutaneous tissue disorders | | | |
| ACNE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ALOPECIA | | | |

| | | |
|-----------------------------|---------------|-----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 |
| DERMATITIS CONTACT | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 |
| DRY SKIN | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 1 |
| ERYTHEMA | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 |
| HAIR GROWTH ABNORMAL | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 |
| HYPERHIDROSIS | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 |
| PETECHIAE | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 |
| PHOTOSENSITIVITY REACTION | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 |
| PRURITUS | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 |
| PRURITUS GENERALISED | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 |
| PSORIASIS | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 |
| RASH | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 |
| RASH GENERALISED | | |

| | | | |
|-----------------------------|---------------|---------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| RASH MACULAR | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| RASH MACULO-PAPULAR | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| RASH PAPULAR | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| RASH PRURITIC | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SKIN EXFOLIATION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SKIN LESION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SKIN TIGHTNESS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| URTICARIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Renal and urinary disorders | | | |
| ANURIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| CHROMATURIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DYSURIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |

| | | | |
|---|----------------|---------------|--|
| POLLAKIURIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| POLYURIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PROTEINURIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| URINARY RETENTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| ARTHRALGIA | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ARTHRITIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| BACK PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| FLANK PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| GOUTY ARTHRITIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| GROIN PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| LIMB DISCOMFORT | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| MUSCLE FATIGUE | | | |

| | | | |
|-----------------------------|---------------|---------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| MUSCLE SPASMS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| MUSCLE TWITCHING | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| MUSCULOSKELETAL CHEST PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| MUSCULOSKELETAL DISCOMFORT | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| MYALGIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| NECK PAIN | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PAIN IN EXTREMITY | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| TENDONITIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Infections and infestations | | | |
| ACARODERMATITIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| CELLULITIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| CYTOMEGALOVIRUS VIRAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |

| | | | |
|-----------------------------|---------------|---------------|--|
| FOLLICULITIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| FUNGAL INFECTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| GASTROENTERITIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HERPES ZOSTER | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HORDEOLUM | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| IMPETIGO | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| INFLUENZA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| LOCALISED INFECTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ORAL CANDIDIASIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| ORAL HERPES | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| OTITIS MEDIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| PHARYNGITIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |

| | | | |
|---|----------------|---------------|--|
| PHARYNGITIS STREPTOCOCCAL | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SINUSITIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| SKIN INFECTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| TINEA CRURIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| TINEA PEDIS | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| TOOTH INFECTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| UPPER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| URINARY TRACT INFECTION | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| VIRAL UPPER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 1 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Metabolism and nutrition disorders | | | |
| DECREASED APPETITE | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DEHYDRATION | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DIABETES MELLITUS | | | |

| | | | |
|--------------------------------------|---------------|---------------|--|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| DIABETES MELLITUS INADEQUATE CONTROL | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| GOUT | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HYPERGLYCAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HYPERKALAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HYPERURICAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HYPOGLYCAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HYPOKALAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HYPOMAGNESAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| HYPONATRAEMIA | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 1 (0.00%) | |
| occurrences (all) | 0 | 0 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---|
| 21 February 2013 | The primary purpose of this amendment was to clarify requirements for rescreening subjects; clarify management of calcineurin inhibitor medications; update inclusion (clarify contraceptives/pregnancy, liver biopsy timeframes) and exclusion criteria (prior history including pegylated interferon [pegIFN] therapy, liver disease, other organ transplant, dietary habits); and clarify study activities. |
| 08 April 2013 | The primary purpose of this amendment was to prohibit the use of hormonal contraceptives during study drug administration. |
| 12 December 2013 | The primary purpose of this amendment was to update the introduction to reflect current case studies and analyses of study data; increase enrollment to 70 subjects; add study arms and further define cohorts 1 and 2; allow enrollment of subjects with interferon (IFN)/ribavirin(RBV) treatment failure, non-cirrhotic subjects with fibrosis scores up to F3 by Metavir Scale (or equivalent score by another scoring system), and subjects with subgenotype 1b who are treatment-naïve or treatment responders; make related updates to the study plan and inclusion and exclusion criteria); update cyclosporine and tacrolimus recommendations based on pharmacokinetic data; clarify blood sample collection; and add hepatitis C virus (HCV) treatment history and response to treatment definitions and collection criteria. |
| 03 October 2014 | The primary purpose of this amendment was to increase enrollment to 145 subjects; add ten study arms (Arms D through M) and further define Cohorts 3, 4, 5, and 6; allow enrollment of subjects with compensated cirrhosis (Child-Pugh A) after liver transplant, subjects who are 3 – 6 months post liver transplant, subjects who are more than 6 and less than 12 months post liver transplant with HCV-related elevation of liver enzymes (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]), and subjects with chronic HCV who are at least 12 months post renal transplant; and make related updates to the study plan, rescreening criteria, and inclusion and exclusion criteria. |
| 08 December 2014 | The primary purpose of this amendment was to increase enrollment to 175 subjects; remove Arms H and K and combine Arms F and I and Arms G and J into a single Cohort (Cohort 4); combine Cohorts 4 and 5 to allow enrollment of subjects ≥ 3 months post liver transplant; change Cohort 6 (Renal Transplant) to Cohort 5; remove language limiting enrollment of renal transplant recipients with a Metavir score of F3 to 5 subjects; and make related update to the study plan and inclusion and exclusion criteria. |
| 13 July 2015 | The primary purpose of this amendment was to increase enrollment to 195; add Cohort 6 (HCV genotype 4-infected subjects post liver transplant); and make related updates to the study and inclusion and exclusion criteria. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported